慢加急性肝衰竭非生物型人工肝支持治疗进展  

Advances in abiotic artificial liver support therapy for acute-on-chronic liver failure

作　　者：袁宏玲 李倩(综述) 覃后继(审校)[1] YUAN Hong-ling;LI Qian;QIN Hou-ji(Youjiang Medical University for Nationalities,Affiliated Hospital of Youjiang Medical University for Nationalities,Youjiang 533000,Guangxi,CHINA)

机构地区：[1]右江民族医学院右江民族医学院附属医院,广西右江533000

出　　处：《海南医学》2023年第7期1039-1043,共5页Hainan Medical Journal

基　　金：北京肝胆相照公益基金会资助课题(编号:RGGJJ-2021-009)。

摘　　要：慢加急性肝衰竭(ACLF)在临床表现上与急性肝衰竭相似,早期较难鉴别,该疾病的临床死亡率极高且预后差,并可在疾病临床病程的任何阶段发生。人工肝支持系统被用做ACLF的一线治疗方法。本文就近年国内外用于治疗ACLF的常用非生物型人工肝模型工作原理、优缺点、适用范围及其治疗研究进展进行述评,以期为临床医生在ACLF治疗过程中对非生物型人工肝的选择提供参考依据。Acute-on-chronic liver failure(ACLF)is clinically similar to acute liver failure,which is difficult to differentiate in the early stage.The disease has a high clinical mortality and poor prognosis,which can occur at any stage of the clinical course.Artificial liver support system is used as the first-line treatment for ACLF.This article reviews the working principle,advantages and disadvantages,application scope and treatment research progress of non-biological artificial liver models commonly used in the treatment of ACLF at home and abroad in recent years,in order to provide reference for clinicians to select non-biological artificial liver for ACLF treatment.

关 键 词：慢加急性肝衰竭 人工肝 肝衰竭 血浆置换 治疗 

分 类 号：R575.3[医药卫生—消化系统]